Ladenburg Thalmann: Corcept Therapeutics SEISMIC Article

In a research report published today by Ladenburg Thalmann, Corcept Therapeutics

has announced the publication of the SEISMIC study in the Journal of Clinical Endocrinology and Metabolism. According to Ladenburg Thalmann, “Specifically, in SEISMIC's glucose intolerant cohort (n=25), antidiabetic medications were reduced in 7 of 15 patients. Additionally, of the 12 patients taking insulin, 5 reduced their daily dose by at least 50%. Therefore, when incorporating effect on medications into the primary endpoint, 18/25 patients (72%) had ≥25% reduction from baseline in AUC-glucose or a reduction in antidiabetic medication (95% CI: 50.6 –87.9%). This compares with a ≥25% decrease from baseline in AUC-glucose in 15/25 (60%) (95% CI lower bound 42%, P< 0.0001).” Ladenburg Thalmann maintains its Buy rating and $7 PT on Corcept Therapeutics, which closed yesterday at $3.96.